DSF has great potential as a treatment for MLL‐fusion‐driven leukaemias due to its known drug profile in humans, low‐cost, little side effects and selectivity against MLL‐rearranged leukaemic cells.46, 66. This evidence concerns the gene KMT2A and leukemia.